Form 4: Carl L. Gordon Reports Beneficial Ownership Changes in Compass Therapeutics, Inc.
SEC Form 4
Carl L. Gordon, a director and 10% owner of Compass Therapeutics, Inc., reports changes in beneficial ownership of common stock due to transactions on April 9, 2025.
Summary
- Carl L. Gordon, a director and 10% owner of Compass Therapeutics, Inc. (CMPX), filed a Form 4 detailing changes in beneficial ownership.
- The report indicates a transaction on April 9, 2025, involving common stock.
- Gordon indirectly holds 3,571,428 shares through OrbiMed Genesis Master Fund, L.P. and 15,219,994 shares through OrbiMed Private Investments V KA, LP.
- The transaction involved the disposition of shares at a price of $1.59.
- Gordon disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions.
Management Comments
- Each of the Reporting Person, GP V, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), except to the extent of his or its pecuniary interest therein, if any.
- This report shall not be deemed an admission that any of the Reporting Person, GP V, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders and large shareholders. This filing indicates activity by a significant shareholder in Compass Therapeutics.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 04/09/2025 | Date of transaction involving common stock |
| 04/11/2025 | Date of signature for the report |
Keywords
beneficial ownership, Form 4, Compass Therapeutics, CMPX, OrbiMed, Carl L. Gordon, securities, common stock, transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.